Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

Many pharmaceutical products made in Europe will face a 15 percent tariff, pinching manufacturers and potentially leading to ...

European pharma companies are breathing a sigh of relief after the Trump administration posed a 15% tariff, rather than 200% ...

Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.

The actual second-quarter results are likely to be less of a focus on Tuesday morning next to broader questions about the strategy to deal with the Keytruda patent expiration. Analysts are ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

Months have passed since Mary Barnes had a double mastectomy to treat an “aggressive” form of breast cancer. Now her treatments have been put on hold because of insurance denials.

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of ...